SCHEMBL15864924

SCHEMBL15864924

COC(=O)c1cc(Cl)cc(OC2CCN(C)CC2)c1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATM Q13315 1/20 0.46
▸ HSP90AA1 P07900 1/20 0.43
▸ HSP90AB1 P08238 1/20 0.43
▸ SCN1A P35498 1/20 0.42
▸ SCN2A Q99250 1/20 0.42
▸ SCN3A Q9NY46 1/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ EZH2 Q15910 1/20 0.41
▸ HTR2C P28335 1/20 0.40
▸ HTR2B P41595 1/20 0.40
▸ HRH1 P35367 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ OPRK1 P41145 1/20 0.40
▸ HTR3E A5X5Y0 1/20 0.40
▸ GMNN O75496 1/20 0.40
▸ HTR3B O95264 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ ALOX15 P16050 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15864679 0.88 EZH2 (0.39) EZH2HRH1OPRK1HTR3EGMNN
SCHEMBL15391354 0.87 PDE5A (0.44) MEN1KMT2AEZH2POLBOPRK1
SCHEMBL15864933 0.87 EZH2 (0.39) MEN1KMT2AEZH2HRH1OPRK1
SCHEMBL15871017 0.85 EZH2 (0.44) MEN1KMT2AEZH2OPRK1HTR3E
SCHEMBL15864876 0.84 EZH2 (0.43) HSP90AB1MEN1KMT2AEZH2HTR2C
SCHEMBL17208276 0.84 EZH2 (0.43) MEN1KMT2AEZH2OPRK1HTR3E
SCHEMBL17201384 0.84 EZH2 (0.43) MEN1KMT2AEZH2OPRK1HTR3E
SCHEMBL15871014 0.84 EZH2 (0.43) MEN1KMT2AEZH2OPRK1HTR3E
SCHEMBL15864890 0.84 KAT2B (0.46) MEN1KMT2AEZH2OPRK1CHEK1
SCHEMBL17201398 0.83 OPRK1 (0.42) MEN1KMT2AEZH2HRH1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9382234-B2 Enhancer of Zeste Homolog 2 inhibitors GLAXOSMITHKLINE LLC (US) 2016-07-05 — — US disclosed
US-9382234-B2 Enhancer of Zeste Homolog 2 inhibitors GLAXOSMITHKLINE LLC (US) 2016-07-05 — — US disclosed
US-9382234-B2 Enhancer of Zeste Homolog 2 inhibitors GLAXOSMITHKLINE LLC (US) 2016-07-05 — — US disclosed
US-20150307480-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE LLC 2015-10-29 — — US disclosed
US-20150307480-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE LLC 2015-10-29 — — US disclosed
US-20150307480-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE LLC 2015-10-29 — — US disclosed
EP-2931707-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS Glaxosmithkline LLC (US) 2015-10-21 — — EP disclosed
WO-2014107277-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE LLC (US) 2014-07-10 — — WO disclosed
WO-2014107277-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE LLC (US) 2014-07-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150307480-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS EZH2, BMI1, EZH1 ATM 1866/4885HSP90AA1 2387/4885HSP90AB1 1694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback